𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Glucose as a prognostic factor in ovarian carcinoma

✍ Scribed by Donald M. Lamkin; Douglas R. Spitz; Mian M. K. Shahzad; Bridget Zimmerman; Daniel J. Lenihan; Koen DeGeest; David M. Lubaroff; Eileen H. Shinn; Anil K. Sood; Susan K. Lutgendorf

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
163 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND:

Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease‐specific survival time and time to recurrence in ovarian cancer patients.

METHODS:

Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease‐free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate.

RESULTS:

Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set.

CONCLUSIONS:

These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma. Cancer 2009. Β© 2009 American Cancer Society.

πŸ“œ SIMILAR VOLUMES

Histologic grade as a prognostic factor
Histologic grade as a prognostic factor in breast carcinoma
✍ Harry B. Burke; Donald Earl Henson πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 47 KB πŸ‘ 2 views

I n this issue of Cancer, Dr. Roberti reviews the role of histologic grade in the prognosis of breast carcinoma and wonders why, because it is available, it has not been widely used in predicting outcome. The position of this editorial is that there must be some fundamental reason, after 100 years

Vascular Endothelial Growth Factor D and
Vascular Endothelial Growth Factor D and Intratumoral Lymphatics as Independent Prognostic Factors in Epithelial Ovarian Carcinoma
✍ Lichun Li; Baoquan Liu; Xuemei Li; Shucai Yang; Jianbing Xiao; Mingwei Chen; Yaf πŸ“‚ Article πŸ“… 2009 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 311 KB πŸ‘ 2 views

## Abstract Lymph node metastasis is an important prognostic indicator for disease progression and is crucial for therapeutic strategies of epithelial ovarian carcinoma. Vascular endothelial growth factor (VEGF)‐D has been confirmed to have potent lymphangiogenic function in experimental models, bu

Tumor ploidy as a major prognostic facto
Tumor ploidy as a major prognostic factor in advanced ovarian cancer
✍ Cees J. Rodenburg; Cees J. Cornelisse; Peter A. M. Heintz; Jo Hermans; Gert Jan πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 575 KB

Tumor ploidy was determined by flowcytometry (FCM) in paraffin-embedded tissue of 74 patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics [FIG01 2B, 3,4). Significant differences in survival and progression-free survival were found between classes of tumor plo